Page last updated: 2024-12-05
3-anisidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-anisidine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10824 |
CHEMBL ID | 1500995 |
CHEBI ID | 194944 |
SCHEMBL ID | 66692 |
MeSH ID | M0045610 |
Synonyms (71)
Synonym |
---|
jxa144kx2i , |
hsdb 7816 |
4-13-00-00953 (beilstein handbook reference) |
unii-jxa144kx2i |
536-90-3 |
nsc-7631 |
3-aminoanisole |
benzenamine, 3-methoxy- |
m-methoxyaniline |
m-aminoanisole |
nsc7631 |
1-amino-3-methoxybenzene |
m-anisylamine |
m-anisidine |
3-methoxyaniline |
NCGC00091221-01 |
inchi=1/c7h9no/c1-9-7-4-2-3-6(8)5-7/h2-5h,8h2,1h |
brn 0386119 |
einecs 208-651-4 |
ai3-52519 |
3-anisidine |
ccris 5886 |
nsc 7631 |
3-methoxybenzenamine |
m-anisidine, 97% |
A0485 |
smr000112350 |
MLS001050108 |
CHEBI:194944 |
AKOS000119110 |
NCGC00091221-02 |
(3-methoxyphenyl)-amine |
3-methoxy aniline |
tox21_200820 |
dtxsid8024529 , |
cas-536-90-3 |
dtxcid604529 |
NCGC00258374-01 |
STL163332 |
A15634 |
3-methoxy-phenylamine |
3-methoxyphenylamine |
FT-0628164 |
PS-4590 |
CHEMBL1500995 |
SCHEMBL66692 |
m-anisidine [hsdb] |
anisidine, m- |
3-methoxy-aniline |
3-methoxy-benzenamine |
3-methoxylaniline |
meta-anisidine |
3-(methyloxy)aniline |
3-methyoxy-aniline |
meta-methoxyaniline |
AM87044 |
Q-200384 |
3-methoxy-1-aminobenzene |
m-aminomethoxybenzene |
3-aminophenol methyl ether |
F2190-0440 |
mfcd00007783 |
AC-10034 |
CS-D1422 |
Q3296585 |
BCP27007 |
14?-hydroxy prednisolone |
EN300-19067 |
104350-19-8 |
F88243 |
Z104472536 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
substituted aniline | |
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (31)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
acetylcholinesterase | Homo sapiens (human) | Potency | 25.3696 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 3.8135 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
AR protein | Homo sapiens (human) | Potency | 0.0112 | 0.0002 | 21.2231 | 8,912.5098 | AID588516 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 25.7661 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.3464 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 12.6921 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 21.8444 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 2.9136 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 27.0181 | 0.0010 | 19.4141 | 70.9645 | AID588537; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 22.0304 | 0.0237 | 23.2282 | 63.5986 | AID743222 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 73.1713 | 0.0007 | 23.0674 | 1,258.9301 | AID743122 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 54.8707 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 22.2758 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Ceullar Components (1)
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) |
plasma membrane | Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) |
plasma membrane | Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 3 (30.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 38.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (38.15) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |